Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Interest Expenses came in at $272.0 million in Q1 2026, up 33.33% year-on-year from $204.0 million in Q1 2025, and up 27.1% quarter-over-quarter from $214.0 million in Q4 2025.
Johnson & Johnson (JNJ) Interest Expenses (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Interest Expenses across 18 years of filings, most recently posting $272.0 million for Q1 2026.
- Interest Expenses for Q1 2026 came in at $272.0 million, up 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 29.23% YoY), and the FY2025 annual result was $971.0 million, up 28.61% from the prior year.
- Interest Expenses came in at $272.0 million for Q1 2026 at Johnson & Johnson, up from $214.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $308.0 million in Q2 2025 to a low of $10.0 million in Q2 2022.
- The 5-year median for Interest Expenses is $193.0 million (2024), against an average of $177.8 million.
- Across the five-year window, Interest Expenses plunged 84.13% in 2022 and jumped 2020.0% in 2023, its largest moves.
- Johnson & Johnson's Interest Expenses stood at $51.0 million in 2022, then surged by 196.08% to $151.0 million in 2023, then dropped by 9.27% to $137.0 million in 2024, then surged by 56.2% to $214.0 million in 2025, then rose by 27.1% to $272.0 million in 2026.
- The last three Interest Expenses figures came in at $272.0 million (Q1 2026), $214.0 million (Q4 2025), and $245.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -225.15 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 272.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | -343.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 272.00 Mn |
| Mar 29, 2026 | 272.00 Mn |
| Dec 28, 2025 | 214.00 Mn |
| Dec 28, 2025 | 214.00 Mn |
| Sep 28, 2025 | 245.00 Mn |
| Sep 28, 2025 | 245.00 Mn |
| Jun 29, 2025 | 308.00 Mn |
| Jun 29, 2025 | 308.00 Mn |
| Mar 30, 2025 | 204.00 Mn |
| Mar 30, 2025 | 204.00 Mn |
| Dec 29, 2024 | 137.00 Mn |
| Dec 29, 2024 | 137.00 Mn |
| Sep 29, 2024 | 193.00 Mn |
| Sep 29, 2024 | 193.00 Mn |
| Jun 30, 2024 | 270.00 Mn |
| Jun 30, 2024 | 270.00 Mn |
| Mar 31, 2024 | 155.00 Mn |
| Mar 31, 2024 | 155.00 Mn |
| Dec 31, 2023 | 151.00 Mn |
| Dec 31, 2023 | 151.00 Mn |